A prospective, 5-week, open-label, randomized, multi-center, parallel-group study with a 20-week, open-label extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5 cm2 rivastigmine patch formulation in patients with probable Alzheimer's disease

Trial Profile

A prospective, 5-week, open-label, randomized, multi-center, parallel-group study with a 20-week, open-label extension evaluating the tolerability and safety of switching from donepezil to an initial dose of 5 cm2 rivastigmine patch formulation in patients with probable Alzheimer's disease

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWAP
  • Sponsors Novartis
  • Most Recent Events

    • 19 May 2009 Results presented at APA 2009.
    • 03 May 2008 Results presented at the 161st Annual Meeting of the American Psychiatric Association 2008.
    • 30 Apr 2008 Results reported at the Annual Scientific Meeting of the American Geriatrics Society (1112825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top